Lab Updates & Announcements
Quest Diagnostics to enhance diagnosis of pediatric neurological disorders with exclusive whole exome sequencing from Personalis
Quest Diagnostics today announced the availability of Neurome?, a whole exome sequencing service designed to aid the diagnosis of rare neurological disorders in pediatric populations.
Athena Diagnostics Launches Next-Gen Testing for Neuromuscular Diseases
Athena Diagnostics is pleased to announce the introduction of next-generation sequencing (NGS) as part of our genetic testing offering for neuromuscular diseases starting February 2nd, 2015.
Methodology and Price Change
The methodology and price has changed for several tests.
Next Generation Sequencing Testing for Epilepsy Available April 2, 2014
Athena Diagnostics is pleased to announce the availability of next-generation sequencing for epilepsy, starting April 2, 2014. Epilepsy is one of the most common serious neurological diseases, characterized by multiple unprovoked seizures (surges of electrical activity in the brain that disrupt function).
Athena Diagnostics is discontinuing the following tests.
SMA Testing Changes
Effective August 15, 2013, the following changes will be made to our Spinal Muscular Atrophy assays.
Athena Diagnostics Announces New Genetic Testing Services for Rare Neurological Disorders
Tests to be unveiled at the American Academy of Neurology | Annual Meeting in San Diego, March 16-23, 2013
Test Code 586 Discontinued: Replaced by 506
Athena Diagnostics has experienced a technical delay in the development of test code 586, the new Male Muscular Dystrophy Reflexive Profile.
CMT Test Offering Notification
New tests now available.
C9orf72 Genetic Test for ALS (Lou Gehrig's Disease)
The company's Athena Diagnostics business unit to unveil the new test at the American Academy of Neurology Annual Meeting this week in New Orleans
Athena Diagnostics Welcomes Joseph J. Higgins, M.D.
Joseph J. Higgins, M.D., has joined Athena Diagnostics as Medical Director for Neurology.